ArticleEpilepsy currents2026
AES-NINDS Epilepsy Benchmarks Area IV: Comorbidities of Epilepsy - Where Are We and Where Will We Go?
Article in Epilepsy currents, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Area IV of the 2021 Epilepsy Research Benchmarks aims to establish research goals to limit or prevent adverse consequences of seizures and their treatment across the life span. In this commentary, we will highlight key advances in Area IV. We will focus here on the comorbidities of epilepsy with special emphasis on neuropsychiatry, the endocrine system, and sudden unexpected death in epilepsy, which were discussed at the Epilepsy Benchmarks Area IV Symposium during the Annual Meeting of the American Epilepsy Society in December 2025.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.